Background: Type 2 Diabetes Mellitus (T2DM) is a Pathobiologically complex metabolic disorder characterized by chronic hyperglycemia, progressive β-cell failure, and systemic insulin resistance, precipitating microvascular and macrovascular sequelae, with persistent metabolic disequilibrium driven by therapeutic inertia, adherence attrition, and inadequacies in structured, patient-centric care paradigms.
Objectives: To systematically delineate the longitudinal efficacy of a protocol-driven, pharmacist-led educational intervention on glycemic indexes, lipid perturbations, anthropometric trajectories, hemodynamic parameters, and patient-reported outcome measures over a 12-month evaluative framework.
Materials and Methods: A prospective, controlled, interventional investigation was conducted encompassing 290 individuals with T2DM, stratified into an interventional arm (n=145) and a standard-care control arm (n=145). The intervention cohort received comprehensive pharmaceutical care, including individualized pharmacotherapeutic counseling, adherence optimization strategies, and structured lifestyle modification reinforcement. Multidimensional clinical and biochemical end points were assessed at predefined intervals (baseline, 3, 6, 9, and 12 months). Statistical analyses were performed using SPSS version 31.0, employing parametric and repeated-measures inferential methodologies, with statistical significance established at p<0.05.
Results: The interventional cohort exhibited statistically robust and clinically meaningful improvements across multiple domains, including reductions in glycated hemoglobin (-1.87%), fasting plasma glucose (-41.75 mg/100 mL), body mass index (-6.44 kg/m²), low-density lipoprotein cholesterol (-20.98 mg/100 mL), and systolic blood pressure (-11.3 mM of mercury) (p<0.001). Concurrently, significant augmentation in medication adherence indexes and health-related quality-of-life metrics was observed relative to the control cohort.
Conclusion: Pharmacist-led educational interventions confer substantial multidimensional benefits, encompassing glycemic optimization, cardiometabolic risk attenuation, and enhancement of patient-centric outcomes, thereby reinforcing their critical integration within contemporary multidisciplinary diabetes care frameworks.
Abstract
Share on Mobile
Scan to access on mobile
Keywords
Clinical Pharmacy Intervention
Glycemic Modulation
Medication Adherence
Pharmacotherapeutic Stewardship
Type 2 diabetes mellitus
INTRODUCTION
Type 2 Diabetes Mellitus (T2DM) constitutes a chronic, progressive, and pathobiologically intricate metabolic derangement characterized by persistent hyperglycemia emanating from the confluence of peripheral insulin resistance and inexorable pancreatic β-cell dysfunction (American Diabetes Association, 2024). It represents a formidable and escalating global health exigency, with prevalence trajectories demonstrating exponential amplification across both industrialized and resource-constrained settings. Epidemiological projections from the International Diabetes Federation delineate an estimated global burden of 537 million affected adults in 2021, anticipated to escalate to 643 million by 2030 and 783 million by 2045 (International Diabetes Federation, 2021).
India, frequently ascribed the epithet "diabetes capital of the world, " bears a disproportionately elevated disease burden, with in excess of 77 million individuals afflicted, thereby constituting a critical public health predicament (Anjana et al., 2023). T2DM is inextricably associated with a constellation of debilitating long-term sequelae, encompassing atherosclerotic cardiovascular disease, diabetic nephropathy, peripheral neuropathy, and retinopathy, cumulatively contributing to augmented morbidity, premature mortality, and unsustainable healthcare expenditure burdens (Fowler, 2018).
The attainment of stringent glycemic homeostasis remains paramount in attenuating the progression of these complications; however, durable metabolic regulation continues to be suboptimal in real-world clinical settings. This inadequacy is multifactorial, encompassing therapeutic inertia, adherence attrition, deficient health literacy, escalating pharmacotherapeutic complexity, and maladaptive lifestyle determinants (Davies et al., 2018). Substantial empirical evidence indicates that approximately 50% of individuals with chronic pathologies exhibit suboptimal adherence to prescribed therapeutic regimens, thereby critically undermining clinical efficacy and longitudinal disease control (Sabaté, 2003).
Beyond glycemic perturbations, T2DM management necessitates comprehensive cardiometabolic risk stratification and modulation, including the correction of dyslipidemia, hypertension, and adiposity-related abnormalities (Grundy, 2016). Atherogenic dyslipidemic profiles characterized by elevated Low-Density Lipoprotein (LDL) cholesterol and triglyceride concentrations, coupled with diminished High-Density Lipoprotein (HDL) cholesterol serve as pivotal drivers in the pathogenesis of atherosclerotic cardiovascular disease within diabetic cohorts (Taskinen, 2002).
Within this paradigm, clinical pharmacists have emerged as indispensable constituents of integrated healthcare delivery systems, facilitating pharmacotherapeutic optimization through targeted medication therapy management, individualized patient counseling, and rigorous monitoring of drug-related outcomes (Hepler and Strand, 1990). Pharmacist-mediated interventions have demonstrated substantial efficacy in augmenting therapeutic adherence, rationalizing pharmacological regimens, and improving clinically relevant end points across chronic disease spectra, including T2DM (Chisholm-Burns et al., 2010).
Robust evidence substantiates that such interventions are associated with significant reductions in glycated hemoglobin concentrations, amelioration of lipid derangements, improved hemodynamic control, and enhancement of health-related quality-of-life indexes (Pousinho et al., 2016a). These interventions typically encompass structured educational frameworks, behavioral modification strategies, identification and resolution of drug-related problems, and longitudinal follow-up, collectively fostering sustained therapeutic benefit (Allemann et al., 2012).
Notwithstanding the expanding evidentiary base, there persists a conspicuous paucity of rigorously designed, long-duration controlled investigations elucidating the comprehensive, multidimensional impact of pharmacist-led interventions across clinical, biochemical, and patient-reported domains. This lacuna is particularly salient within the Indian healthcare milieu, wherein disproportionate patient loads and constrained physician-patient interaction intervals necessitate augmented, pharmacist-integrated care models (Basu and Sharma, 2021).
Accordingly, the present investigation was undertaken to systematically elucidate the impact of a protocol-driven, pharmacist-led educational intervention on glycemic regulation, lipid perturbations, anthropometric indexes, hemodynamic parameters, renal safety profiles, and patient-reported outcome measures over a 12-month longitudinal follow-up in individuals with type 2 diabetes mellitus.
MATERIALS AND METHODS
Study Design and Setting
This investigation was conceptualized as a prospective, controlled, longitudinal, interventional study designed to evaluate the clinical impact of pharmacist-led educational interventions in patients with Type 2 Diabetes Mellitus (T2DM). The study was conducted in a tertiary-care teaching hospital over a 12-month observational horizon, incorporating systematic follow-up assessments at predefined temporal intervals (baseline, 3, 6, 9, and 12 months). The institutional setting facilitated access to a diverse patient population, enabling real-world evaluation of multidisciplinary diabetes management strategies. Ethical approval was obtained from the Institutional Ethics Committee, and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Study Population and Sampling
A total of 290 patients diagnosed with T2DM and demonstrating suboptimal glycemic control were enrolled and stratified into two parallel cohorts: an interventional group (n=145) and a control group (n=145). Participants were recruited using a systematic and purposive sampling framework to ensure representativeness and minimize selection bias.
Inclusion Criteria
• Adults aged ≥18 years with a confirmed diagnosis of T2DM.
• Patients exhibiting inadequate glycemic control (HbA1C ≥7%).
• Individuals receiving oral antidiabetic therapy, including SGLT-2 inhibitors or DPP-4 inhibitors.
• Willingness to provide informed consent and adhere to study follow-up.
Exclusion Criteria
• Patients with type 1 diabetes mellitus or gestational diabetes.
• Critically ill patients or those requiring intensive care support.
• Individuals with advanced renal, hepatic, or cardiovascular compromise.
• Pregnant or lactating women.
• Patients with incomplete clinical records or anticipated poor compliance.
Study intervention
The interventional cohort was subjected to a structured, pharmacist-led educational intervention model, encompassing comprehensive pharmaceutical care. This included individualized pharmacotherapeutic counseling, medication reconciliation, identification and resolution of drug-related problems, adherence enhancement strategies, and structured lifestyle modification guidance focusing on diet, physical activity, and self-monitoring practices.
Regular reinforcement sessions were conducted during each follow-up visit to ensure continuity of care and sustained behavioral modification. The control cohort received standard medical care without structured pharmacist involvement.
Data Collection and Study Variables
Baseline data were systematically recorded using a prevalidated case record form, including demographic characteristics, clinical history, comorbidities, and medication profiles.
The following parameters were assessed at baseline and during follow-up visits:
Glycemic Parameters
• Fasting Blood Sugar (FBS).
• Postprandial Blood Sugar (PPBS).
• Glycated Hemoglobin (HbA1C).
Lipid Profile
• Total cholesterol.
• LDL.
• HDL.
• Triglycerides.
• Very Low Density Lipoprotein (VLDL).
Anthropometric Parameters
• Body Weight.
• Body Mass Index (BMI).
Hemodynamic Parameters
• Systolic Blood Pressure (SBP).
• Diastolic Blood Pressure (DBP).
Renal and Metabolic Safety Parameters
• Serum creatinine.
• Blood urea.
• Uric acid.
Electrolyte Profile
• Serum sodium.
• Serum potassium.
• Serum chloride.
• Serum calcium.
Patient-Reported Outcomes
• Medication adherence (using validated adherence scales).
• Quality of life (using standardized assessment tools).
Outcome Measures
Primary outcome
• Change in HbA1C levels from baseline to 12 months.
Secondary outcomes
• Changes in glycemic indexes (FBS, p.p.b.).
• Modifications in lipid profile parameters.
• Alterations in anthropometric and hemodynamic variables.
• Safety outcomes (renal and metabolic parameters).
• Improvement in medication adherence and quality of life.
Study procedure
Following enrollment and baseline assessment, patients in the interventional group received structured educational sessions delivered by clinical pharmacists. Follow-up evaluations were conducted at 3, 6, 9, and 12 months, during which all clinical and biochemical parameters were reassessed.
Drug-related problems were identified, documented, and resolved in collaboration with treating physicians. The control group underwent routine clinical evaluation without additional pharmacist-mediated input.
Statistical analysis
Data were analyzed using SPSS software (Version 31.0). Continuous variables were expressed as mean±Standard Deviation (SD), while categorical variables were presented as frequencies and percentages.
• Within-group comparisons: paired t-test.
• Between-group comparisons: independent samples t-test.
• Longitudinal analysis: repeated measures Anova.
• Categorical variables: χ2 test Post-hoc analyses were performed using Bonferroni and Sidak corrections. Statistical significance was defined at p<0.05.
Ethical considerations
Written informed consent was obtained from all participants before study inclusion. Confidentiality of patient data was strictly maintained, and all procedures adhered to institutional ethical guidelines and international standards for biomedical research.
Data quality assurance
To ensure methodological rigor, standardized protocols were implemented for data collection and laboratory measurements. Periodic data validation and cross-verification were performed to enhance accuracy and reproducibility.
RESULTS
Baseline Demographic and Clinical Characteristics
Baseline characteristics were comparable between the interventional (n=145) and control (n=145) cohorts. Gender distribution showed no statistically significant difference (p=0.744). However, a significant difference in mean age was observed (p<0.0001), with variation across age categories. The interventional group had a higher proportion of patients aged 46-55 years (44.1%), whereas the control group was predominantly within 56-65 years (46.2%) (Table 1).
Residence distribution (urban vs. rural) did not differ significantly (p=0.066). Duration of diabetes was similar across both groups, with most patients having a disease duration of 6-10 years, indicating baseline comparability of clinical characteristics.
Anthropometric Parameters (Weight and BMI)
A progressive and statistically significant reduction in anthropometric parameters was observed in the interventional group. Mean body weight declined from 69.50±2.50 kg at baseline to 63.50±2.70 kg at 12 months (Δ -6.00 kg; p<0.001). Similarly, BMI decreased from 29.57±2.68 to 23.13±2.09 (Δ -6.44; p<0.001).
In contrast, the control group exhibited negligible, nonsignificant changes in both weight and BMI across all time points, indicating minimal impact without intervention (Table 2).
Glycemic Parameters (FBS, p.p.b., HbA1C)
The interventional group demonstrated substantial and sustained improvement in glycemic control over 12 months. Fasting blood glucose decreased from 198.55 to 156.80 mg/100 mL (Δ -41.75 mg/100 mL), while postprandial glucose reduced from 284.25 to 227.14 mg/100 mL (Δ -57.11 mg/100 mL). HbA1C levels declined significantly from 9.12 to 7.25% (Δ -1.87%), indicating effective long-term glycemic regulation. Although improvements were also observed in the control group, the magnitude of change was considerably lower, confirming the superiority of pharmacist-led intervention (Table 3).
Hemodynamic and Lipid Parameters
Significant improvements were observed in cardiovascular risk parameters within the interventional cohort. Systolic blood pressure decreased from 140.20 to 128.62 mM of mercury (Δ -11.3 mM of mercury), and diastolic blood pressure from 89.01 to 81.01 mM of mercury (Δ -8.00 mM of mercury).
Lipid profile analysis demonstrated favorable modulation, with reductions in total cholesterol (205.85-185.85 mg/100 mL), triglycerides (156.10-136.15 mg/100 mL), LDL cholesterol (128.79-107.81 mg/100 mL), and VLDL levels. HDL cholesterol showed a notable increase (47.13-55.15 mg/100 mL). The control group exhibited only marginal improvements, indicating limited cardiometabolic benefit without structured intervention (Table 4).
Renal, Metabolic, and Electrolyte Parameters
Renal and metabolic safety parameters remained largely stable across the study duration. In the interventional group, serum creatinine showed a minimal increase (0.94-0.98 mg/100 mL), while urea demonstrated a slight elevation. Notably, uric acid levels significantly decreased (6.31-4.98 mg/100 mL).
Electrolyte analysis revealed minor fluctuations within physiological limits. Sodium and potassium levels showed slight reductions, while chloride levels exhibited a modest increase. Serum calcium remained stable, indicating overall metabolic safety and tolerability of the intervention (Table 5).
HbA1C).
Patient Outcomes, Prescription Patterns, and Drug Safety
Significant improvements in patient-reported outcomes were observed in the interventional group. Medication adherence scores increased from 5.00 to 8.00, while quality-of-life scores improved from 5.50 to 7.96 over 12 months.
Prescription pattern analysis revealed that monotherapy was the most common treatment approach (58.2%), followed by fixed-dose combinations (31.9%). Among monotherapy drugs, gliclazide, glimepiride, and metformin were the most frequently prescribed agents.
Insulin utilization was predominantly observed with Human Mixtard, 19.3%, followed by Humalog Mix and insulin glargine.
A total of 18 drug-related adverse events were identified, with gastrointestinal disturbances being the most frequent, followed by skin reactions and hypoglycemic episodes. All adverse events were appropriately managed without major clinical complications (Table 6).
Table 4 Hemodynamic and lipid parameters.
| Parameter | Group | Baseline | 12 months | Δ | p-value |
|---|---|---|---|---|---|
| SBP (mmHg) | interventional | 140.2 | 128.62 | -11.3 | <0.001*** |
| control | 137 | 134.7 | -2.5 | 0.002** | |
| DBP (mmHg) | interventional | 89.01 | 81.01 | -8.00 | <0.001*** |
| control | 84.6 | 82.6 | -2.00 | 0.008** | |
| Total cholesterol | interventional | 205.85 | 185.85 | -20.00 | <0.001*** |
| control | 205.3 | 200.3 | -5.00 | 0.007** | |
| Triglycerides | interventional | 156.1 | 136.15 | -19.95 | <0.001*** |
| control | 158.35 | 149.13 | -9.22 | <0.001*** | |
| HDL | interventional | 47.13 | 55.15 | 8.02 | <0.001*** |
| control | 47.11 | 49.11 | 2 | <0.001*** | |
| LDL | interventional | 128.79 | 107.81 | -20.98 | <0.001*** |
| control | 128.04 | 125.29 | -2.75 | <0.05* | |
| VLDL | interventional | 39.86 | 31.82 | -8.04 | <0.001*** |
| control | 39.32 | 37.59 | -1.73 | <0.05* | |
| Abbreviations:DBP: Diastolic Blood Pressure; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; SBP: Systolic Blood Pressure; VLDL: Very Low-Density Lipoprotein. | |||||
Table 5 Renal, metabolic and electrolyte parameters.
| Parameter | Group | Baseline | 12 months | Δ | p-value |
|---|---|---|---|---|---|
| Urea | interventional | 18.61 | 19.77 | 1.16 | 0.001 (NS) |
| control | 17.82 | 16.55 | -1.27 | 0.001*** | |
| Creatinine | interventional | 0.94 | 0.98 | 0.04 | <0.001*** |
| control | 1.04 | 1 | -0.04 | <0.001*** | |
| Uric acid | interventional | 6.31 | 4.98 | -1.34 | <0.001*** |
| control | 5.86 | 5.82 | -0.05 | <0.05* | |
| Sodium | interventional | 143.13 | 139.13 | -4.00 | <0.001*** |
| control | 139.87 | 139.72 | -0.15 | 0.214 (NS) | |
| Potassium | interventional | 4.47 | 4.06 | -0.41 | <0.001*** |
| control | 4.44 | 4.45 | 0.01 | 0.300 (NS) | |
| Chloride | interventional | 98.81 | 102.77 | 3.96 | <0.001*** |
| control | 99.41 | 99.39 | -0.02 | 1.000 (NS) | |
| Calcium | interventional | 9.45 | 9.44 | -0.01 | 1.000 (NS) |
| control | 9.04 | 9.44 | 0.4 | <0.001** |
DISCUSSION
The present prospective, controlled investigation furnishes robust, longitudinally sustained evidence delineating the multidimensional therapeutic superiority of pharmacist-mediated educational interventions in the comprehensive management of Type 2 Diabetes Mellitus (T2DM). The integrative interpretation of findings derived from Tables 1-7 elucidates a coherent pattern of statistically rigorous and clinically consequential ameliorations spanning glycemic, cardiometabolic, anthropometric, biochemical, and patient-reported domains.
The baseline demographic and clinical equilibrium between the interventional and control cohorts Table 1, evidenced by statistically nonsignificant intergroup differentials across gender stratification, residential distribution, and disease chronicity (p>0.05), substantiates methodological robustness and mitigates potential confounding biases. Such cohort comparability is indispensable for ensuring internal validity and aligns with methodological paradigms reported in landmark glycemic outcome studies (Stratton et al., 2000).
A pronounced and temporally progressive attenuation of anthropometric indexes was observed within the interventional arm Table 2, with a substantial decrement in BMI (Δ-6.44 kg/m²; p<0.001) and body weight, in stark contrast to the negligible fluctuations within the control cohort. This sustained anthropometric regression underscores the efficacy of pharmacist-driven behavioral modulation and therapeutic reinforcement strategies. These observations exhibit concordance with large-scale interventional trials wherein structured lifestyle modification and continuous patient engagement culminated in significant weight reduction and metabolic recalibration (Look AHEAD Research Group, 2013).
The glycemic trajectory (Table 3) demonstrated a profound and statistically robust decrement across all indexes within the intervention cohort, including FBS (-41.75 mg/100 mL), p.p.b. (-57.11 mg/100 mL), and HbA1C (-1.87%) (p<0.001). The magnitude of HbA1C reduction surpasses established thresholds of clinical significance and reflects optimized pharmacotherapeutic adherence, regimen individualization, and sustained educational reinforcement. These findings are congruent with prior controlled and meta-analytic evaluations, wherein pharmacist-integrated care models yielded HbA1C reductions ranging between 0.8 and 1.5%, thereby substantiating the translational efficacy of such interventions (Ali et al., 2012; Chisholm-Burns et al., 2010).
Hemodynamic and lipidic modulations (Table 4) further accentuate the cardioprotective ramifications of pharmacist-led care. The substantial reductions in systolic (-11.3 mM of mercury) and diastolic (-8.00 mM of mercury) blood pressures, coupled with favorable lipid remodeling characterized by LDL diminution (-20.98 mg/100 mL) and HDL augmentation (+8.02 mg/100 mL) collectively signify comprehensive attenuation of atherogenic risk. These multidimensional improvements parallel findings from systematic reviews and meta-analyses demonstrating significant cardiovascular risk mitigation through pharmacist-directed interventions (Machado et al., 2007; Santschi et al., 2014).
Renal and metabolic indexes (Table 5) remained largely within physiological stability, with a notable decrement in serum uric acid levels (-1.34 mg/100 mL; p<0.001) in the intervention group, potentially indicative of improved metabolic homeostasis and reduced oxidative stress milieu. Electrolytic homeostasis was preserved, with only clinically inconsequential variations, thereby reaffirming the safety and tolerability of intensified pharmaceutical care. These findings are corroborative of longitudinal safety assessments within pharmacist-managed cohorts, wherein no deleterious renal or metabolic perturbations were observed (Carter et al., 2009).
Patient-reported outcomes (Table 6) exhibited substantial and statistically significant enhancement, particularly in medication adherence and health-related quality-of-life indexes (p<0.001). The augmentation of adherence scores underscores the pivotal role of pharmacists in mitigating nonadherence-a well-recognized impediment to optimal therapeutic outcomes. Concurrent improvements in quality-of-life metrics reflect enhanced disease cognition, self-efficacy, and therapeutic satisfaction. These observations resonate with prior evidence highlighting the psychosocial and behavioral impact of pharmacist-led interventions (Krass et al., 2007; Sabater-Hernández et al., 2016).
The comprehensive between-group comparative analysis (Table 7) unequivocally demonstrates statistically significant superiority of the interventional cohort across all evaluated parameters, including BMI, glycemic indexes, lipid fractions, and hemodynamic variables (p<0.01). The magnitude and consistency of these intergroup differentials underscore the clinical indispensability of pharmacist-led interventions within multidisciplinary diabetes care frameworks. Comparable magnitudes of effect have been reported in systematic reviews and randomized evaluations, further reinforcing the external validity of the present findings (Nkansah et al., 2010; Pousinho et al., 2016b; Wubben and Vivian, 2008). Additionally, the discernible reduction in drug-related problems and adverse drug reactions Table 6 highlights the critical role of clinical pharmacists in pharmacovigilance, therapeutic optimization, and minimization of iatrogenic risk. This aligns with seminal investigations demonstrating a significant decline in medication-related complications following pharmacist integration into clinical care pathways (Leape et al., 1999).
Table 1 Baseline demographic and clinical characteristics.
| Parameter | Category | Interventional (n=145) | Control (n=145) | p-value |
|---|---|---|---|---|
| Gender | Male | 76 (52%) | 73 (50%) | 0.744 (NS) |
| Female | 69 (48%) | 72 (50%) | ||
| Age (mean±SD) | Years | - | - | <0.0001 |
| Age distribution | 35-45 | 21 (14.5%) | 44 (30.3%) | |
| 46-55 | 64 (44.1%) | 30 (20.7%) | ||
| 56-65 | 46 (31.7%) | 67 (46.2%) | ||
| 66-75 | 14 (9.7%) | 4 (2.8%) | ||
| Residence | Urban | 84 (57.9%) | 65 (44.8%) | 0.066 (NS) |
| Rural | 61 (42.1%) | 80 (55.2%) | ||
| Duration of diabetes | ≤5 years | 30 (20.7%) | 48 (33.1%) | |
| 6-10 years | 68 (46.9%) | 54 (37.2%) | ||
| 11-15 years | 35 (24.1%) | 33 (22.8%) | ||
| >15 years | 12 (8.3%) | 10 (6.9%) |
Table 2 Anthropometric parameters (weight and Body Mass Index [BMI]).
| Time | Group | Weight (kg) mean±SD | Δ | BMI mean±SD | Δ | p-value |
|---|---|---|---|---|---|---|
| Baseline | interventional | 69.50±2.50 | - | 29.57±2.68 | - | - |
| control | 66.50±2.40 | - | 27.90±1.16 | - | - | |
| 3 months | interventional | 67.8 | -1.70 | 27.96 | -1.61 | <0.001 |
| control | 66.45 | -0.05 | 27.88 | -0.02 | NS | |
| 6 months | interventional | 66.1 | -3.40 | 26.33 | -3.24 | <0.001 |
| control | 66.4 | -0.10 | 27.85 | -0.05 | NS | |
| 9 months | interventional | 64.8 | -4.70 | 24.72 | -4.85 | <0.001 |
| control | 66.45 | -0.05 | 27.83 | -0.07 | NS | |
| 12 months | interventional | 63.5 | -6.00 | 23.13 | -6.44 | <0.001 |
| control | 66 | 0 | 27.8 | -0.10 | NS | |
| Abbreviations: BMI: Body Mass Index. | ||||||
Table 3 Glycemic parameters (Fasting Blood Sugar [FBS], p.p.b., HbA1C).
| Time | Group | FBS (mg/100 mL) | Δ | p-value | p.p.b. (mg/100 mL) | Δ | p-value | HbA1C (%) | Δ | p-value |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | interventional | 198.55 | - | - | 284.25 | - | - | 9.12 | - | - |
| control | 199.3 | - | - | 245 | - | - | 9.18 | - | - | |
| 3 months | interventional | 188.5 | -10.05 | <0.001*** | 269.6 | -14.65 | 0.003** | 8.62 | -0.50 | 0.004** |
| control | 195.5 | -3.80 | 0.120 (NS) | 235 | -10.00 | 0.038* | 8.89 | -0.29 | 0.031* | |
| 6 months | interventional | 179 | -19.55 | <0.001*** | 255.22 | -29.03 | <0.001*** | 8.13 | -0.99 | <0.001*** |
| control | 190.4 | -8.90 | 0.022* | 225 | -20.00 | 0.006** | 8.63 | -0.55 | 0.003** | |
| 9 months | interventional | 168.5 | -30.05 | <0.001*** | 241.15 | -43.10 | <0.001*** | 7.69 | -1.43 | <0.001*** |
| control | 186.7 | -12.60 | 0.004** | 215 | -30.00 | 0.001** | 8.36 | -0.82 | 0.001** | |
| 12 months | interventional | 156.8 | -41.75 | <0.001*** | 227.14 | -57.11 | <0.001*** | 7.25 | -1.87 | <0.001*** |
| control | 182.9 | -16.40 | 0.001** | 205 | -40.00 | <0.001*** | ||||
| Abbreviations: FBS: Fasting Blood Sugar. | ||||||||||
Table 6 Patient outcomes, prescription Pattern and safety.
| Parameter | Category | Value | p-value |
|---|---|---|---|
| Medication adherence | interventional | 5.00 → 8.00 | <0.001*** |
| control | 6.00 → 9.67 | <0.001*** | |
| Quality of life | interventional | 5.50 → 7.96 | <0.001*** |
| control | 4.95 → 6.35 | <0.001*** | |
| Prescription pattern | monotherapy | 58.20% | - |
| FDC | 31.90% | - | |
| other | 9.90% | - | |
| Top drugs | gliclazide | 14.40% | - |
| glimepiride | 13.50% | - | |
| metformin | 12.05% | - | |
| Insulin use | Human Mixtard | 19.30% | - |
| Humalog Mix | 16.70% | - | |
| glargine | 16% | - | |
| Drug-related problems | total ADRs | 18 | - |
| Abbreviations: ADRs: Adverse Drug Reaction. | |||
Table 7 Overall, between-group comparison of key parameters (12-month change from baseline).
| Parameter | Interventional Group Δ (12m-baseline) | Control group Δ (12m-baseline) | Between-Group p-value | Significance |
|---|---|---|---|---|
| BMI (kg/m²) | -6.44 | -0.10 | <0.001*** | significant |
| HbA (%)1c | -1.87 | -1.05 | 0.002** | significant |
| FBS (mg/100 mL) | -41.75 | -16.40 | <0.001*** | significant |
| p.p.b. (mg/100 mL) | -57.11 | -40.00 | <0.001*** | significant |
| Total cholesterol (mg/100 mL) | -20.00 | -5.00 | <0.001*** | significant |
| Triglycerides (mg/100 mL) | -19.95 | -9.22 | <0.001*** | significant |
| HDL-C (mg/100 mL) | 8.02 | 2 | 0.004** | significant |
| LDL-C (mg/100 mL) | -20.98 | -2.75 | <0.001*** | significant |
| VLDL-C (mg/100 mL) | -8.04 | -1.73 | 0.003** | significant |
| SBP (mmHg) | -11.3 | -2.5 | <0.001*** | significant |
| DBP (mmHg) | -8.00 | -2.00 | <0.001*** | significant |
| Uric acid (mg/100 mL) | -1.34 | -0.05 | <0.001*** | significant |
| Abbreviations: BMI: Body Mass Index; DBP: Diastolic Blood Pressure; FBS: Fasting Blood Sugar; SBP: Systolic Blood Pressure. | ||||
CONCLUSION
In summation, the present study elucidates that pharmacist-led educational interventions engender profound, sustained, and multidimensional therapeutic benefits encompassing glycemic optimization, cardiometabolic risk attenuation, pharmacotherapeutic safety, and enhancement of patient-centric outcomes. These findings robustly advocate for the systematic incorporation of clinical pharmacists into standard diabetes care paradigms, particularly within resource-constrained healthcare systems where continuity of care and patient education remain suboptimal.
The present investigation unequivocally substantiates that pharmacist-led educational interventions confer a statistically robust and clinically meaningful enhancement across glycemic, cardiometabolic, and patient-reported outcome domains. The sustained attenuation of hyperglycemia, optimization of lipid indexes, and augmentation of adherence and quality-of-life metrics collectively delineate the indispensable role of clinical pharmacists within integrated, multidisciplinary diabetes care architectures. These findings advocate for the systematic institutionalization of pharmacist-driven models to mitigate therapeutic inertia and optimize long-term disease trajectories.
CLINICAL IMPLICATIONS
The findings of the present investigation possess substantial translational relevance, underscoring the pivotal integration of clinical pharmacists within routine diabetes care frameworks. The demonstrated improvements in glycaemic indices, cardiometabolic parameters, and adherence metrics advocate for the incorporation of pharmacist-mediated interventions as a standard-of-care adjunct, particularly in resource-constrained healthcare settings characterized by high patient burden and limited physician interaction time.
In summation, this study delineates the transformative impact of pharmacist-led educational interventions in T2DM management, encompassing glycemic optimization, cardiovascular risk attenuation, and enhancement of patient-centric parameters. The findings reinforce the paradigm shift toward collaborative, pharmacist-integrated care models as a cornerstone for achieving superior clinical and therapeutic outcomes.
FUTURE DIRECTIONS
Future investigations should encompass multicentric, randomized controlled trials with larger and more heterogeneous populations to enhance external validity. Additionally, incorporation of digital health platforms, pharmacogenomic profiling, and cost-effectiveness analyses may further elucidate the scalability and precision of pharmacist-led interventions in chronic disease management.
STRENGTHS OF THE STUDY
The study is distinguished by its prospective controlled design, extended 12-month follow-up duration, and comprehensive evaluation of multidimensional endpoints, including biochemical, hemodynamic, anthropometric, and patient-reported outcomes. The integration of real-world clinical practice settings further augments its pragmatic applicability and translational significance.
LIMITATIONS
Despite its methodological rigor, the study is constrained by its single-center design and finite sample size, potentially limiting broader generalizability. Additionally, reliance on patient-reported adherence measures may introduce subjective bias. The absence of blinding and potential interobserver variability may further influence outcome interpretation.
Abbreviations
T2DM: Type 2 Diabetes Mellitus
FBS: Fasting Blood Sugar
PPBS: Postprandial Blood Sugar
HbA1C: Glycated Hemoglobin
BMI: Body Mass Index
SBP: Systolic Blood Pressure
DBP: Diastolic Blood Pressure
LDL: Low-Density Lipoprotein
HDL: High-Density Lipoprotein
VLDL: Very Low-Density Lipoprotein.
Acknowledgments
The authors express their profound gratitude to all study participants for their invaluable cooperation and adherence throughout the study duration. We extend sincere appreciation to the institutional authorities and healthcare professionals for facilitating the execution of this research. Special acknowledgment is accorded to the clinical pharmacy team for their dedicated involvement in intervention delivery and patient monitoring.
Conflict of Interest
The authors declare that there is no conflict of interest.
References
Ali, M., Schifano, F., Robinson, P., Phillips, G., Doherty, L., Melnick, P., Dhillon, S.. (2012). Impact of community pharmacy diabetes monitoring and education programme on diabetes management: A randomized controlled study. Diabetic Medicine, 29(9), e326-e333. https://doi.org/10.1111/j.1464-5491.2012.03725.x10.1111/j.1464-5491.2012.03725.x
Allemann, S. S. v. M. J. W. B. L. B. K. G. N. H. K. E. e. a.. (2012). pharmaceutical care and adherence in diabetes. Diabetes Care, 35(12), 2706-2712.
American Diabetes Association. (2024). Classification and diagnosis of diabetes. Diabetes Care, 47(Suppl. 1), S16-S33.
Anjana, R. M., Deepa, M., Pradeepa, R., Mahanta, J., Narain, K., Das, H. K., et al.. (2023). Prevalence of diabetes in India. Lancet Diabetes Endocrinology, 11(1), 45-54. https://doi.org/10.1016/s2213-8587(23)00296-6
Basu, S., Sharma, N.. (2021). Role of pharmacists in India. International Journal of Clinical Pharmacy, 43(3), 567-575. https://doi.org/10.1007/s11096-021-01279-2
Carter, B. L., Rogers, M., Daly, J., Zheng, S., James, P. A., et al.. (2009). Clinical pharmacist intervention effects on blood pressure. Archives of Internal Medicine, 169, 1996-2002. https://doi.org/10.1001/archinternmed.2009.358
Chisholm-Burns, M. A., Kim Lee, J. K., Spivey, C. A., Slack, M., Herrier, R. N., Hall-Lipsy, E., Wunz, T.. (2010). US pharmacists' effect on patient outcomes. Medical Care, 48(10), 923-933. https://doi.org/10.1097/MLR.0b013e3181e57962
Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Buse, J. B.. (2018). Management of hyperglycaemia in type 2 diabetes. Diabetes Care, 41(12), 2669-2701. https://doi.org/10.2337/dci18-0033
Fowler, M. J.. (2018). Microvascular and macrovascular complications of diabetes. Clinical Diabetes, 36(1), 11-17. https://doi.org/10.2337/diaclin.26.2.77
Grundy, S. M.. (2016). Metabolic syndrome and cardiovascular risk. Circulation, 134(5), e26-e27.
Hepler, C. D., Strand, L. M.. (1990). Opportunities and responsibilities in pharmaceutical care. American Journal of Health-System Pharmacy, 47(3), 533-543. https://doi.org/10.1093/ajhp/47.3.533
International Diabetes Federation. (2021). IDF diabetes atlas (10th ed).
Krass, I., Armour, C. L., Mitchell, B., Brillant, M., Dienaar, R., Hughes, J., et al.. (2007). Impact of pharmacy services on outcomes in type 2 diabetes. Diabetes Research and Clinical Practice, 75, 339-350. https://doi.org/10.1016/j.diabres.2006.06.022
Leape, L. L., Cullen, D. J., Clapp, M. D., Burdick, E., Demonaco, H. J., Erickson, J. I., et al.. (1999). Pharmacist participation in physician rounds. JAMA, 282, 267-270.
Look AHEAD Research Group. (2013). Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors. New England Journal of Medicine, 369(2), 145-154. https://doi.org/10.1056/NEJMoa1212914
Machado, M., Bajcar, J., Guzzo, G. C., Einarson, T. R., et al.. (2007). Sensitivity of patient outcomes to pharmacist interventions. Diabetes Care, 30, 1639-1643. https://doi.org/10.1345/aph.1k151
Nkansah, N., Mostovetsky, O., Yu, C., Chheng, T., Beney, J., Bond, C. M., Bero, L.. (2010). Effect of pharmacist interventions on patient outcomes. Cochrane Database of Systematic Reviews, 2011(1), CD000336. https://doi.org/10.1002/14651858.CD000336.pub2
Pousinho, S., Morgado, M., Falcão, A., Alves, G., et al.. (2016a). Pharmacist interventions in type 2 diabetes mellitus. Journal of Managed Care and Specialty Pharmacy, 22(5), 493-515. https://doi.org/10.18553/jmcp.2016.22.5.493
Pousinho, S., Morgado, M., Falcão, A., Alves, G., et al.. (2016b). Pharmacist interventions in diabetes management. Journal of Managed Care and Specialty Pharmacy, 22, 493-515. https://doi.org/10.18553/jmcp.2016.22.5.493
Sabaté, E.. (2003). Adherence to long-term therapies: Evidence for action.
Sabater-Hernández, D., Sabater-Galindo, M., Fernandez-Llimos, F., Rotta, I., Hossain, L. N., Durks, D., et al.. (2016). Effectiveness of pharmacist interventions. Annals of Pharmacotherapy, 50, 529-540. https://doi.org/10.18553/jmcp.2016.22.6.699
Santschi, V., Chiolero, A., Paradis, G., Colosimo, A. L., Burnier, M., et al.. (2014). Pharmacist interventions to improve cardiovascular risk factors. Journal of the American Heart Association, 3, e000718. https://doi.org/10.2337/dc12-0369
Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A.. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ, 321(7258), 405-412. https://doi.org/10.1136/bmj.321.7258.405
Taskinen, M. R.. (2002). Diabetic dyslipidaemia. Atherosclerosis Supplements, 3(1), 47-51. https://doi.org/10.1016/S1567-5688(01)00006-X
Wubben, D. P., Vivian, E. M.. (2008). Effects of pharmacist outpatient interventions on diabetes outcomes. Pharmacotherapy, 28(4), 421-436. https://doi.org/10.1592/phco.28.4.421